What is sivextro used for?

What does Sivextro treat?

Sivextro is an antibiotic used to treat certain bacterial skin infections. It targets gram-positive bacteria, including MRSA, and works against strains that have developed resistance to other antibiotics.

Does it work against MRSA?

Sivextro contains tedizolid, an oxazolidinone class antibiotic. It stops bacteria from making proteins they need to live. It proves effective against MRSA and other methicillin-resistant staphylococci in clinical studies.

What infections does it cover?

Sivextro treats acute bacterial skin and skin structure infections (ABSSSI). These include cellulitis, erysipelas, and wound infections. The FDA approved it in 2014 for adults and pediatric patients six years and older.

How does it compare with linezolid?

Sivextro is a newer version of linezolid. It requires a shorter treatment course of six days compared to linezolid’s fourteen days. It has a lower risk of side effects like bone marrow suppression.

How is Sivextro administered?

Sivextro comes as tablets or an intravenous infusion. Patients can switch from the IV form to the tablet form without losing the infection control effect.

When does Sivextro’s patent expire?

Sivextro’s patent expires in 2028. Biosimilars or generics may enter the market after that date.

What side effects do patients report?

Patients ask about nausea, diarrhea, and headache. The drug also has a risk of peripheral neuropathy and serotonin syndrome when combined with other drugs.

Who manufactures Sivextro?

Nabriva Therapeutics owns the rights to Sivextro. The company acquired it from Cubist Pharmaceuticals after the ursprüngliche owner was sold to Merck.